Page 18 - Improved Quality News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AACE e-ECE clinical data previously presented at Endocrine Society’s 2021 annual meeting NEEDHAM, Mass., May 20, 2021 (GLOBE NEWSWIRE) Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it will virtually present encore data from its MPOWERED™ Phase 3 clinical trial at the 23 rd European Congress of Endocrinology (e-ECE) (May 22-26, 2021) and new data from the MPOWERED trial at the 30 th Annual American Association of Clinical Endocrinology (AACE) Meeting (May 26-29, 2021).

United statesPatrick burseyMurrayb gordonPamela fredaAshley robinsonAnthonyp heaneyMaria fleseriuNienke biermaszEuropean congressLifesci advisorsEndocrine societyLarge international noninferiority trialChiasma incColumbia universityExchange commissionLifesci communications